Laddar populära aktier...
Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial
Biosergen samtycker till accelererad dosökning i den pågående andra kohorten i den kliniska prövningen
The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 20...
Nyttjandeperioden för Biosergen ABs (”Biosergen” eller ”Bolaget”) teckningsoptioner av serie TO3 (”Teckningsoptionerna”) löpte ut den 29 nov...
Biosergen AB (”Biosergen” eller "Bolaget") meddelar idag utfallet från nyttjandet av teckningsoptionerna av serie TO3, vilka emitterades i s...
Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in conn...
26 november, 2024 - Biosergen AB (”Biosergen”), ett bioteknikbolag i klinisk fas som utvecklar behandlingar för livshotande svampinfektioner...
November 26, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infe...
Today, November 26, 2024, is the last day of trading with the warrants of series TO3 (the “Warrants”)in Biosergen AB (”Biosergen” or the "Co...
Idag, den 26 november 2024, är den sista dagen för handel med teckningsoptioner av serie TO3 (”Teckningsoptionerna”) i Biosergen AB (”Bioser...
November 21, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal dise...
Biosergen AB (”Biosergen” eller "Bolaget") har erhållit teckningsförbindelser och toppgarantiåtaganden om totalt cirka 44,9 MSEK motsvarande...
Biosergen AB (”Biosergen” or the "Company") has received subscription commitments and top underwriting commitments totaling approximately SE...
Biosergen AB (”Biosergen” eller "Bolaget") slutförde under första kvartalet 2024 en företrädesemission av units, beståendes av aktier och te...
Biosergen AB (”Biosergen” or the "Company") completed a rights issue during the first quarter of 2024, consisting of shares and warrants of ...
So far, the majority of patients involved in Biosergen’s proof-of-concept study for life-threatening fungal infections have been able to lea...
Majoriteten av de hittills behandlade patienterna med livshotande svampinfektioner i Biosergens proof-of-concept-studie har kunnat lämnat sj...
Biosergen publicerar delårsrapport för tredje kvartalet 2024
Biosergen publishes interim report for third quarter 2024
7. november 2024 - Biosergen AB (”Biosergen”), ett bioteknikbolag i klinisk fas som utvecklar behandlingar för livshotande svampinfektioner,...
November 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infec...
Biosergen recently announced the completion of treatment for the first cohort of patients in its proof-of-concept trial for its antifungal d...
Biosergen meddelade nyligen slutförandet av den första kohorten av patienter i sin proof-of-concept-studie med den svampdödande läkemedelska...
Biosergen slutför den första kohorten i den kliniska studien BSG005, som visar lovande potential vid läkemedelsresistenta svampinfektioner
Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections
Biosergen utvecklar läkemedelskandidaten BSG005, utformad som en räddningsbehandling för patienter med invasiva livshotande svampinfektioner...
Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections.
7. Oktober 2024 - Biosergen AB (”Biosergen”), ett bioteknikbolag i klinisk fas som utvecklar behandlingar för livshotande svampsjukdomar, me...
October 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseas...
In Biosergen’s Q2 report, the company highlights the successful start of the phase Ib study with BSG005.
I Biosergens Q2-rapport lyfter bolaget fram den framgångsrika starten på fas Ib-studien med BSG005.
Biosergen - Optimism after treatment success – Mangold Insight Analysis
Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2024.
Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby announce the completion of treatment of the first patient with B...
Biosergen har tillsammans med indiska Alkem inlett patientstudier med läkemedelskandidaten BSG005 mot svampsjukdomar.
Biosergen has together with Indian Alkem initiated patient studies with its drug candidate BSG005 for fungal diseases.
Den första patienten har blivit doserad i Biosergens kliniska fas Ib-studie med BSG005, som utvecklas som en livräddande behandling för krit...
The first patient has been dosed in Biosergen’s clinical phase Ib trial with BSG005, intended as rescue therapy for invasive fungal infectio...
Stockholm, Sweden – July 12, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that the first patient suffering from an invasive fung...
Today, on June 14, 2024, the annual general meeting was held in Biosergen AB.
Stockholm, Sweden – June 11, 2024 – Based on the change in ownership during successful capital raise earlier this year major shareholders in...
Stockholm, Sweden – June 11, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that it has received permission to test BSG005 as resc...
During Q1, Biosergen took major steps towards its goal to address the hidden threat of fungal infections.
Under första kvartalet tog Biosergen viktiga steg mot sitt mål att adressera det dolda hotet från svampinfektioner.
Friday, May 31, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the first quarter 2024.
The shareholders of Biosergen AB, Reg. No. 559304-1295, (the “Company”) are invited to attend the annual general meeting to be held on Frida...
The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation have announced a USD 300 million initiative to support soluti...
Novo Nordisk Foundation, Wellcome och Bill & Melinda Gates Foundation satsar 300 miljoner USD för att stödja forskning som adresserar stora ...
Friday, May 10, 2024: Biosergen AB (“Biosergen” or the “Company”) publishes annual report for the financial year 2023.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES,...
I BioStock Studio berättar svenska Biosergen om sin vision, marknadsplan och strategi för att ta sin produkt genom den första patientstudien...
In the BioStock Studio, Swedish Biosergen talks about the company’s vision, market plan and strategy to take its product through the first p...
Biosergen AB (publ) (“Biosergen” or the “Company”) announce that members of the board of directors, through affiliated companies, management...
Recently having closed a partnership deal with Alkem, Biosergen is advancing its antifungal drug candidate BSG005 through clinical studies.
Biosergen ingick nyligen ett samarbetsavtal med Alkem och avancerar sin svampdödande läkemedelskandidat BSG005 genom kliniska studier.
How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyot...
Hur stort är hotet från svampinfektioner och de stammar som blivit resistenta? Det svenska bolaget Biosergen utvecklar antimyotiska läkemede...
Biosergen är aktuella med en företrädesemission om 40,5 Mkr som ska finansiera en first-in-patient säkerhets- och effektstudie med läkemedel...
Biosergen is carrying out a SEK 40.5 million rights issue to conduct a first-in-patient safety and efficacy study with the antifungal drug c...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUST...
At an extraordinary general meeting in Biosergen AB (publ) (the “Company”) on 1 March 2024, the below resolutions were adopted.
Thursday, February 29, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the fourth quarter 2023.
Stockholm, Sweden – February 12, 2024 – Biosergen AB (“Biosergen” or the “Company is pleased to announce that it has received permission to ...
The shareholders of Biosergen AB, Reg. No. 559304-1295, are invited to attend an extraordinary general meeting to be held on Friday 1 March ...
Stockholm, Sweden – January 12, 2024 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the dev...
Biosergen will conduct a new phase 1b study in patients with invasive fungal infections with its drug candidate BSG005.
Stockholm, Sweden – December 12, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the de...
Thursday, November 30, 2023: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2023.
Biosergen AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).
Stockholm, Sweden – October 23, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the dev...
Stockholm, September 25, 2023: Biosergen AB (Biosergen) and Alkem Laboratories Ltd.
Stockholm, Sweden - August 28, 2023 – Biosergen AB ("Biosergen" or the “Company") today announces the outcome of the exercise of warrants se...
Stockholm, Sweden - August 22, 2023 - Today is the last day of trading in warrants series TO2 in Biosergen AB (“Biosergen” or the “Company”)...
Stockholm, Sweden – August 16 – Biosergen AB ("Biosergen" or the “Company"), a clinical stage biotech company specializing in the developmen...
Monday, August 14, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2023.
Stockholm, Sweden - August 11, 2023 - Biosergen AB ("Biosergen" or the “Company") completed a rights issue of units on Nasdaq First North Gr...
Biosergen publish financial report for second quarter ahead of schedule.
Stockholm, Sweden – August 7, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical stage biotech company specializing in the devel...
Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023
Wednesday, May 31, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the first quarter 2023.
Today, on May 31, 2023, the annual general meeting was held in Biosergen AB.
Wednesday, May 10, 2022: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2022 annual report is available on the compan...
The shareholders of Biosergen AB, Reg. No. 559304-1295, are invited to attend the annual general meeting to be held on Wednesday 31 May 2023...
Biosergen. that develops a drug for the treatment of invasive fungal diseases, has successfully completed phase 1 studies in March.
Biosergen, som utvecklar ett läkemedel för behandling av invasiva svampsjukdomar, har framgångsrikt slutfört fas 1-studier i mars.
Friday, March 31, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the fourth quarter 2022.
Stockholm, Sweden – March 29, 2023 – Biosergen AB (“Biosergen” or the “Company”), today announced an update of the Company’s Phase 2 clinica...
Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29
Biosergen will be participating at Mangold Insight Investor Day, March 22
Carlsquare has initiated its coverage of Biosergen
March 13, 2023: Biosergen today announced completion of the phase 1 study with BSG005.
Mangold Insight initiate coverage of the biotechnology company Biosergen with a buy recommendation and a price target of SEK 2.
Mangold Insight tar upp bevakning på bioteknikbolaget Biosergen med rekommendationen köp och riktkurs 2,70 kronor per aktie.
January 16, 2023: Biosegen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee has approved escalation to the...
December 12, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the first volunteer in the MAD part of the Phase I study...
Wednesday, November 30, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2022.
